GulamAbbasManjiMDPhD

Gastrointestinal Cancer, Hematologic Oncology, Sarcoma

Assistant Professor

Overview of Dr. Manji

Dr. Gulam Manji is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Ross University School of Medicine and has been in practice 8 years. He is one of 370 doctors at New York-Presbyterian Hospital and one of 121 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 40 publications and over 500 citings.

Office
161 Fort Washington Ave
New York, NY 10032
Book by Phone+1(234) 657-1990

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2012 - 2015
Albany Medical CenterResidency, Internal Medicine, 2009 - 2012
Ross University School of MedicineClass of 2009

Certifications & Licensure

OH State Medical License 2024 - 2026
NY State Medical License 2012 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2015 Nov 04
Active, not recruiting
Phase 1, Phase 2
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma Start of enrollment: 2019 Nov 01
Terminated
Phase 2

Publications & Presentations

PubMed

Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer.
Karie Runcie, Yadriel Bracero, Avishai Samouha, Gulam Manji, Helen E Remotti
The Oncologist. 2025-01-17
Low Bacterial Biomass in Human Pancreatic Cancer and Adjacent Normal Tissue.
Michael S May, Heekuk Park, Dalia H Moallem, Dwayne Seeram, Sun Dajiang
International Journal of Molecular Sciences. 2024-12-27
Trends in the Care of Locally Advanced Pancreatic Cancer in the Modern Era of Chemotherapy.
Alexander S Thomas, Parisa Tehranifar, Wooil Kwon, Nupur Shridhar, Kazuki N Sugahara
Journal of Surgical Oncology. 2024-12-01

Lectures

Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral ...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Researchers Discover How Pancreatic Cancer Cells Evade StarvationNovember 3rd, 2020
BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic CancerOctober 29th, 2020
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)February 29th, 2024
Join now to see all

Grant Support

Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancerCOLUMBIA UNIVERSITY HEALTH SCIENCES2022–2027
Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancerCOLUMBIA UNIVERSITY HEALTH SCIENCES2022–2027
Elucidation and targeting of paracrine cascades in PDACCOLUMBIA UNIVERSITY HEALTH SCIENCES2022–2027